MENU
UTMD
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

UTMD stock forecast, quote, news & analysis

Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable, and for hospital use... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
A.I.Advisor
a Summary for UTMD with price predictions
Nov 10, 2026

UTMD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 27, 2026

UTMD may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 26 of 39 cases where UTMD's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 67%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where UTMD's RSI Indicator exited the oversold zone, 11 of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 44%.

The Moving Average Convergence Divergence (MACD) for UTMD just turned positive on November 09, 2026. Looking at past instances where UTMD's MACD turned positive, the stock continued to rise in 33 of 51 cases over the following month. The odds of a continued upward trend are 65%.

UTMD moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +2.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where UTMD advanced for three days, in 137 of 245 cases, the price rose further within the following month. The odds of a continued upward trend are 56%.

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on UTMD as a result. In 62 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.

The 10-day moving average for UTMD crossed bearishly below the 50-day moving average on October 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 53%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where UTMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 51%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. UTMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 75 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 82 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.879) is normal, around the industry mean (4.964). P/E Ratio (22.021) is within average values for comparable stocks, (40.591). Projected Growth (PEG Ratio) (5.980) is also within normal values, averaging (4.143). Dividend Yield (0.017) settles around the average of (0.005) among similar stocks. P/S Ratio (6.549) is also within normal values, averaging (56.876).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. UTMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
published Dividends

UTMD paid dividends on October 05, 2026

Utah Medical Products UTMD Stock Dividends
А dividend of $0.31 per share was paid with a record date of October 05, 2026, and an ex-dividend date of September 17, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.78B. The market cap for tickers in the group ranges from 126 to 159.96B. ISRG holds the highest valuation in this group at 159.96B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 2%. For the same Industry, the average monthly price growth was 6%, and the average quarterly price growth was 23%. ZJYL experienced the highest price growth at 55%, while NXGL experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was 17% and the average quarterly volume growth was -24%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 58
P/E Growth Rating: 53
Price Growth Rating: 49
SMR Rating: 81
Profit Risk Rating: 93
Seasonality Score: 21 (-100 ... +100)
UTMD in upward trend: price may ascend as a result of having broken its lower Bollinger Band on October 27, 2026